CTNNB1 and breast cancer: Dose-dependent reduction in cancer specific mortality in breast cancer patients with > 21 MET-h/wk (multivariate adjusted RR = 0.51, p < 0.05), in men&women with CTNNB1-negative colorectal cancer patients with > 18 MET-h/wk (multivariate adjusted RR = 0.33,p < 0.05).